Angiotensin-converting enzyme inhibitors (ACEi) are indicated in the management of hypertension, heart failure, and diabetic nephropathy in both young and elderly patients [1]. Most patients tolerate ACE inhibitors well, but around 30% can develop adverse reactions like symptomatic hypotension and dry cough, however, more severe adverse reactions, including angioedema and renal failure, can also occur [2-4]. The gene discussed is ACE; the disease is diabetic kidney disease.